MedPath

AMBRX, INC.

AMBRX, INC. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2003-01-01
Employees
101
Market Cap
-
Website
http://www.ambrx.com

Clinical Trials

5

Active:1
Completed:2

Trial Phases

2 Phases

Phase 1:2
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (60.0%)
Phase 1
2 (40.0%)

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Phase 2
Withdrawn
Conditions
HER2 Mutation-Related Tumors
HER2 Amplified Solid Tumors
Interventions
First Posted Date
2021-09-13
Last Posted Date
2022-09-13
Lead Sponsor
Ambrx, Inc.
Registration Number
NCT05041972
Locations
🇺🇸

Mount Sinai Medical Center, Miami Beach, Florida, United States

🇺🇸

AMR Kansas City, Kansas City, Missouri, United States

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Phase 2
Recruiting
Conditions
HER2 Positive Metastatic Breast Cancer
Interventions
First Posted Date
2021-04-02
Last Posted Date
2025-01-20
Lead Sponsor
Ambrx, Inc.
Target Recruit Count
71
Registration Number
NCT04829604
Locations
🇰🇷

Research Site, Suwon, Korea, Republic of

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Phase 1
Completed
Conditions
Gastric Neoplasm
Solid Tumors
Breast Neoplasms
Interventions
First Posted Date
2017-08-21
Last Posted Date
2024-02-01
Lead Sponsor
Ambrx, Inc.
Target Recruit Count
106
Registration Number
NCT03255070
Locations
🇺🇸

USC Norris Cancer Hospital, Los Angeles, California, United States

🇺🇸

UCLA Hematology-Oncology, Santa Monica, California, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

and more 6 locations

Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).

Phase 2
Completed
Conditions
Growth Hormone Deficiency
Interventions
First Posted Date
2008-10-23
Last Posted Date
2009-10-12
Lead Sponsor
Ambrx, Inc.
Target Recruit Count
36
Registration Number
NCT00778518
Locations
🇭🇺

Accelsiors CRO and Consultancy Services, Budapest, Hungary

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.